Participating Companies


Abide Tx
Serine hy­dro­lase-tar­get­ed ther­a­peu­tics har­ness­ing the en­do­cann­abi­noid sys­tem to ad­dress neu­ro­log­i­cal and pain di­s­or­ders w. limit­ed or no treat­ment op­tions. Ph 2: Tourette Syn­drome on­go­ing with da­ta ex­pect­ed in 1Q20; Ph 1b: neu­ro­path­ic pain com­plete, with plans to ini­ti­ate Ph 2 in 1H19. [more in­for­ma­tion]
Affimed N.V. [AFMD] US$187 MM MCap
Mo­d­u­lar ROCK™plat­form en­abling mul­ti-spe­cif­ic NK / T-cell bi-and tri-spe­cif­ic Abs. Aug 2018 deal w Ge­nen­tech ($96M up­front / $5B po­ten­tial). – AFM13 in P1b (com­bo) in HL and P2a(mono) in CD30+lym­pho­ma [more in­for­ma­tion]
Anterra Capital
An­ter­ra is the lead­ing biotech in­ves­tor in the plant and an­i­mal sci­ence in­dus­tries. An­ter­ra part­n­ers close­ly with biotech com­pa­nies to speed the ap­pli­ca­tion of emerg­ing tech­nolo­gies across life sci­ence sec­tors. Backed fi­nan­cial­ly and strate­g­i­cal­ly by Fi­del­i­ty and Rabobank, An­ter­ra is the pre­mi­er fund for plant and an­i­mal biotech in­vest­ing. [more in­for­ma­tion]
AxoGen [AXGN] US$846 MM MCap
Da­m­age or tran­sec­tion to pe­ripher­al nerves. Q1 revs $23.3M, 35% growth YoY; exp 2019 rev bt $109-$114M [more in­for­ma­tion]
Biohaven Pharmaceuticals, Inc [BHVN] US$2,677 MM MCap
Lead de­vel­op­ment pro­grams in­clude mul­ti­ple com­pounds across its CGRP re­cep­tor an­ta­g­on­ist and glu­ta­mate mo­d­u­la­tion plat­forms. In­ter­nal de­vel­op­ment and re­search with in­tel­lec­tu­al prop­er­ty li­censed from com­pa­nies and in­sti­tu­tions in­clud­ing BMS, As­traZene­ca, Yale Uni­ver­si­ty, Ca­ta­l­ent, ALS Bio­phar­ma and Mas­sachusetts Gen­er­al Hos­pi­tal. [more in­for­ma­tion]
Carisma Therapeutics Inc.
Pi­oneer­ing the de­vel­op­ment of CAR macrophages, a dis­rup­tive ap­proach to im­munother­a­py. The tech­nol­o­gy lev­er­ages ad­vances in macrophage bi­ol­o­gy, chimer­ic anti­gen re­cep­tor en­gi­neer­ing and adop­tive cel­lu­lar ther­a­py for the treat­ment of hu­man dis­ease. [more in­for­ma­tion]
Cellectis SA [CLLS] US$715 MM MCap
Lead in­ter­nal pro­gram UCART123, an off-the-shelf CAR-T ther­a­peu­tic, in Ph 1 for the treat­ment of AML and BPD­CN. Al­lo­gene / Servi­er-part­nered UCART19 off-the-shelf CAR-T is cur­rent­ly be­ing studied in Ph 1 studies for the treat­ment of pe­di­a­tric and adult ALL. [more in­for­ma­tion]
CTI BioPharma [CTIC] US$50 MM MCap
Lead can­di­date pa­cri­tinib, oral ki­nase in­hibi­tor w spe­ci­fic­i­ty for JAK2, FLT3, IRAK1, and CS­F1R in Ph 2 for treat­ment of myelo­fi­bro­sis. Up­com­ing ca­t­alysts: pa­cri­tinib PAC203 Ph 2 da­ta - mid'19, ini­ti­a­tion of ph3 - Q3. [more in­for­ma­tion]
CureVac AG
Found­ing Co of mR­NA space (last round $1bn+). In­tra­tu­mo­ral ther­a­py Ph1 (mul­ti­ple onc in­di­ca­tions) ini­ti­at­ed Q4 17, ear­ly da­ta rep at SITC. First pt en­rolled Ph 1 pro­phy­lac­tic mR­NA ra­bies vax Oct 2018. Pro­phy­lac­tic in­fluen­za vax ini­ti­a­tion Ph 1 2020, OTC de­fi­cien­cy Ph 1 ini­ti­a­tion H219. In­ter­im da­ta /all trials: 2019. [more in­for­ma­tion]
EOC Pharma
EOC is a Shang­hai-based bio­phar­ma­ceu­ti­cal com­pany that is fo­cused on the in-li­cens­ing of in­no­va­tive glob­al on­col­o­gy prod­ucts, and de­vel­op­ing, man­u­fac­tur­ing and com­mer­cial­iz­ing them for the Chi­na mar­ket. [more in­for­ma­tion]
Evofem Biosciences, Inc. [EVFM] US$172 MM MCap
Se­cured $30M strate­g­ic in­vest­ment from PDL Bio­S­ciences (PDLI) in April 2019 for 6.7M shares at $4.50 (26% pre­mi­um to pri­or day close) and 25% war­rant cov­er­age. [more in­for­ma­tion]
Hutchison China MediTech Ltd ("Chi-Med") [HCM] US$3,596 MM MCap
Fruquin­tinib (VEG­FR in­hibi­tor, LLY-part­nered) for col­orec­tal can­cer was ap­proved in Chi­na in Septem­ber 2018 and Phase 3 to­p­line re­sults in NS­CLC is ex­pect­ed in late 2018. AZN has the de­ci­sion on strat­e­gy for Phase 3 reg­is­tra­tion and po­ten­tial Break­through Ther­a­py in NS­CLC in com­bi­na­tion with Ta­gris­so. [more in­for­ma­tion]
I-Mab Biopharma
The com­pany built its strong pipe­line with strong in­ter­nal re­search sup­ple­ment­ed with ac­tive li­cens­ing from lead­ing glob­al bio­phar­ma part­n­ers such as best in class sg­p130 molecules from Fer­ring, unique CD38 mAb from Mor­phosys, and mul­ti­ple late stage molecules from Genexine. [more in­for­ma­tion]
Kadmon Holdings, Inc. [KDMN] US$282 MM MCap
Plat­form of ROCK in­hibi­tors. ROCK2 in­hibi­tor in reg­is­tra­tion trial cGVHD; en­roll­ment com­ple­tion exp 2H19; ini­tial anal­y­sis exp YE. Ph 2 ini­ti­a­tion in scle­ro­der­ma exp in 2019. [more in­for­ma­tion]
Mabspace Biosciences
MabS­pace Bio­s­ciences fo­cus­es on the dis­cov­ery and de­vel­op­ment of anti­body-based ther­a­peu­tics for can­cer and fi­brot­ic dis­eas­es. MabS­pace has pro­grams in­hibit­ing Wnt sig­nal­ing path­way and en­hanc­ing BMP sig­nal­ing path­way for the treat­ment of fi­brot­ic di­s­or­ders for both lung and kid­ney dis­eas­es. [more in­for­ma­tion]
Medigene AG [MDG1:DB] €202 MM MCap
blue­bird bio col­lab; BLUE ini­ti­at­ing trial w/MDG MAGEA-4 can­di­date in 2020. TCRs tar­get­ing HA-1 & MAGE-A1 in de­vt. . DC vax in on­go­ing Ph 1/2; fi­nal read­out in 2019. [more in­for­ma­tion]
Medivir AB [MVIR.B-SE]
Late stage broad pipe­line: remeti­no­s­tat, Ph 3 ready top­i­cal HDAC in­hibi­tor for ear­ly-stage cu­ta­neous T-cell lym­pho­ma; MIV-711, cathepsin K in­hibi­tor for OA, Ph 2 da­ta showed dis­ease mod­i­fy­ing ef­fect on knee struc­ture; birini­pant, bi­va­lent SMAC mimet­ic read out pos­i­tive Ph 1/2 com­bo (keytru­da) da­ta Oct 18: con­firmed PR, good safe­ty. [more in­for­ma­tion]
Minerva Neurosciences, Inc. [NERV] US$211 MM MCap
Ph 3 tar­get­ing neg symp­toms as­soc w/ schi­zophre­nia; to­p­line re­sults exp 4Q19. 3 Ph 2b trials on­go­ing w/Janssen MDD/in­som­nia. (+) to­p­line Ph 2 b da­ta w/20mg dose; in­som­nia read­out exp 2Q19 [more in­for­ma­tion]
Motif Bio plc [MTFB] US$30 MM MCap
PD­U­FA date: Feb 13, 2019 for Antibi­ot­ic Iclaprim. Two Phase 3 trials in pts w acute bac­te­rial skin and skin struc­ture in­fec­tions (ABSS­SI) achieved pri­mary and se­condary end­points. Com­pared to SoC (van­comycin), no ob­served nephro­tox and a fixed dose. Po­ten­tial other in­di­ca­tions in­clude HABP/VABP and S. au­reus lung in­fec­tions in CF (or­phan). [more in­for­ma­tion]
Nanobiotix SA [NANO:PA] €231 MM MCap
Nano­bi­otix is a lead­ing, clin­i­cal-stage nanomedicine com­pany pi­oneer­ing new ap­proach­es to sig­ni­f­i­cant­ly change pa­tient out­comes by bring­ing nano­physics to the heart of the cell. Nano­bi­otix’s Im­muno-On­col­o­gy pro­gram has the po­ten­tial to bring a new di­men­sion to can­cer im­munother­a­pies. [more in­for­ma­tion]
NeuroRx
De­vel­op­ing first Glx tar­get­ed an­tide­pres­sant to ad­dress sui­ci­dal­i­ty in bipo­lar de­pres­sion. Lead can­di­date, NRX-101 in Ph 2b/3 de­vt (Break­thru Desig­na­tion, SPA and Fast Track Desig­na­tion by FDA) for Se­vere Bipo­lar De­pres­sion in pts w Acute Sui­ci­dal Idea­tion and Be­havior. Plans to pre­sent Ph 2 POC da­ta lat­er this year. [more in­for­ma­tion]
NexImmune, Inc.
Anti­gen-spe­cif­ic T cell ther­a­py. Syn­thet­ic nano­par­ti­cles de­c­o­rat­ed w a com­bo of mul­ti­ple tu­mor rel­e­vant anti­gens and co-sti­m­u­la­to­ry sig­nals en­gag­ing di­rect­ly w tar­get­ed T cells. Mul­ti­ple IND fil­ings exp H1'19. [more in­for­ma­tion]
Oncopeptides AB [ONCO:ST] SKr7,492 MM MCap
Melflufen (Yga­lo): alky­lat­ing pep­tide se­lec­tive­ly tar­gets MM; su­pe­ri­or ef­fi­ca­cy vs. SOC. In­ter­im da­ta at EHA (2018) from on­go­ing Ph2 study in late stage r/r MM showed ORR of ~32%. [more in­for­ma­tion]
Oryzon Genomics [ORY:MA]
Tar­get­ing ly­sine spe­cif­ic demethy­lase 1 (LS­D1, aka KD­M1A). Lead CNS com­pound in 3 Phase 2a trials in MS, AD and bas­ket trial. Onc com­pound in 2 com­bo Phase 2a trials in AML and SCLC. Da­ta exp mid-2019 [more in­for­ma­tion]
Pharming Group NV [PHARM:AS] €492 MM MCap
On­ly prod­uct with fu­ture po­ten­tial to be ap­proved for both pro­phy­laxis and treat­ment of at­tacks of HAE. An­nounced pos­i­tive re­sults from a ph2 study of RU­CON­EST in Con­tract-in­duced Nephro­pa­thy for pa­tients re­ceiv­ing elec­tive coro­nary an­giog­ra­phy with or with­out a per­cu­ta­neous coro­nary in­ter­ven­tion (PCI). [more in­for­ma­tion]
PhaseBio Pharmaceuticals, Inc. [PHAS] US$303 MM MCap
De­vel­op­ing ther­a­pies for treat­ment of or­phan dis­eas­es; Al­so de­vel­op­ing PB1046, a week­ly va­soac­tive in­testi­nal pep­tide re­cep­tor ag­on­ist for treat­ment of PAH. PB1046 lev­er­ages pro­pri­e­tary elastin-like po­lypep­tide (ELP) biopo­ly­mer tech­nol­o­gy plat­form to de­vel­op ther­a­pies with po­ten­tial for less-fre­quent dos­ing and bet­ter pa­tient com­pliance. [more in­for­ma­tion]
Phosphagenics [PPGNY] US$1 MM MCap
Plat­form en­hances us­a­bil­i­ty char­ac­teris­tics for in­jecta­bles, patch and gel prod­ucts. Part­n­er­ships w No­var­tis and Themis: Do­clofenac Gel for Pain and in­flam­ma­tion due to mus­cle, ten­don and joint in­juries; mar­ket­ed in 16 coun­tries. Teru­mo part­n­er­ship: Propo­fol in­jec­tion; My­lan part­n­er­ship: Dap­to­mycin Lyophil­ized Pow­der for IV In­jec­tion. [more in­for­ma­tion]
Pieris Pharmaceuticals, Inc. [PIRS] US$184 MM MCap
An­ti­calins (en­gi­neered lipo­calin pro­teins) for re­sp & on­co dis­eas­es. Im­mi­nent da­ta for AZN-part­nered PRS-060 in­haled IL4 for mod-to-se­vere asth­ma. Cash of $128MM in the bank as of March 2019. [more in­for­ma­tion]
Poxel SA [POXEL:PA] €181 MM MCap
Imeglimin (mi­to­chon­dria-based MOA) for T2D be­gan Ph 3 in Ja­pan with Asian part­n­er Su­m­i­t­o­mo Dainip­pon. Com­ple­tion of Phase 3 on track for 2019 and JN­DA sub­mis­sion in 2020. In 1Q18, an­nounced agree­ment w Roi­vant for Imeglimin (Ph 3 ready) in US, EU, and ad­dl coun­tries WW. [more in­for­ma­tion]
Protagonist Therapeutics [PTGX] US$256 MM MCap
PTG-300, in­jectable hep­cidin mimet­ic in Ph 2 Be­ta-Tha­lassemia study with ini­tial re­sults ex­pect­ed 2H19. PTG-200, part­nered w Janssen, oral GI-re­strict­ed IL-23R an­ta­g­on­ist for Crohn’s dis­ease com­plet­ed Ph 1 in Novem­ber 2018. PN-943, oral GI-re­strict­ed al­pha4­be­ta7 in­te­grin-spe­cif­ic an­ta­g­on­ist in UC in Ph 1, with to­p­line re­sults ex­pect­ed 1H19. [more in­for­ma­tion]
PsiOxus Therapeutics
The ther­a­py (NG-348), us­es virus to tran­s­port two ther­a­peu­tic genes di­rect­ly in­to tu­mors to re­cruit im­mune cells in­to at­tack­ing tar­get­ed can­cer cells. Up­com­ing Mile­s­tones: - 2 pro­grams in clin­ic with read­outs in 2019 (ovarian can­cer in comb w Pa­cl­i­tax­el, car­ci­no­mas in comb w nivolumab) - 2 INDs in 2018 (NG-348 and NG-350A) - 2 INDs in 2019 (NG-641 and NG-347) [more in­for­ma­tion]
Rumi Scientific
Th­ese em­bry­oids faith­ful­ly mod­el hu­man de­vel­op­ment and when cou­pled with CRIS­PR-CAS9 genome en­gi­neer­ing, they pro­vide unique pheno­typ­ic sig­na­tures of hu­man di­s­or­ders that can be pre­cise­ly an­a­lyzed by ma­chine-learn­ing al­go­rithms to dis­cov­er new ther­a­peu­tics for cur­rent­ly in­cur­able dis­eas­es. [more in­for­ma­tion]
Savara Inc. [SVRA] US$421 MM MCap
Or­phan lung dis­ease; Mol­gradex, Ph 3, in­haled GM-CSF: au­toim­mune pul­mo­nary alve­o­lar pro­tei­no­sis (aPAP), Ph 2a: non­tu­ber­cu­lous my­cobac­te­ria (NTM) lung in­fec­tion [more in­for­ma­tion]
Strongbridge Biopharma [SBBP] US$161 MM MCap
Fo­cused on rare dis­eas­es; Keveyis for PPP 2019 rev­enue gui­dance of $18-20M; Re­cor­lev 2nd Phase 3 top-line re­sults by end of 1Q 2020 with NDA sub­mis­sion planned for 3Q 2020 [more in­for­ma­tion]
Targovax [TRVX:OS] NKr421 MM MCap
En­gi­neered on­co­lyt­ic virus armed w im­mune-sti­m­u­lat­ing trans­genes for pts w solid tu­mors. Ph 1 and Ph 1/2 trials on­go­ing with mul­ti­ple da­ta read­outs in 2019-2020. CMO de­vel­oped Yer­voy at BMS. [more in­for­ma­tion]
Vericel Corporation [VCEL] US$690 MM MCap
Ad­vanced cell ther­a­py; mar­ket­ing MA­CI (car­ti­lage re­pair) and Epi­cel (skin re­place­mentt) in TAMs of $2b+. Re­cent­ly ac­quired US com­mer­cial rights for Nexo­Brid. [more in­for­ma­tion]
Veru Inc. [VERU] US$110 MM MCap
Zu­clomiphene in Ph 2 treat­ing hot flash­es caused by hor­mone treat­ment for pros­tate can­cer. Ad­vanc­ing 4 new drug for­mu­la­tions in urol­o­gy: Ta­dala­fil/fi­nas­teride com­bo tablets for symp­toms of BPH and erec­tile dys­func­tion (NDA fil­ing exp 2H19). Tam­su­losin DRS gran­ules and XR cap­sules for be­nign pro­stat­ic hy­per­pla­sia (BPH) treat­ment w/o food ef­fect (NDA fil­ing exp 2019). [more in­for­ma­tion]